[Feature Stock] HLB Pharmaceutical Confirms 1st Issuance Price for Capital Increase at 5,650 Won... Capital Increase Schedule Intensifies Ahead of Ex-Rights Trading
HLB Pharmaceutical has confirmed the first issuance price for its rights offering at 5,650 won per share, aiming to raise approximately 60.8 billion won for facility and operational funds. Ex-rights trading is scheduled for August 4th.
Key takeaway
"[Feature Stock] HLB Pharmaceutical Confirms 1st Issuance Price for Capital Increase at 5,650 Won... Capital Increase Schedule Intensifies Ahead of Ex-Rights Trading" — BullBear's AI rates this story as a bearish (negative) signal for markets, with a market-impact score of 50 out of 100. HLB Pharmaceutical has confirmed the first issuance price for its rights offering at 5,650 won per share, aiming to raise approximately 60.8 billion won for facility and operational funds. Ex-rights trading is scheduled for August 4th. Reported by TokenPost on August 03, 2026. The call is verified against the actual 24-hour price move on BullBear's public conviction ledger.
Catch the next bear flag
Telegram alerts when our AI scores a story 80+/100 impact (~1-3 per day, no spam). Verified 30d hit rate 49.8%.